Yazar "Ozkan, M." seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; Multicenter observational study(Imprimatur Publications, 2011) Saip, P.; Keskin, S.; Ozkan, M.; Kaplan, M. A.; Aydogan, F.; Demirag, G. Gonullu; Uzunoglu, S.Purpose: To determine the time elapsed between the first notification of the disease and the access to the diagnosis and treatment modalities and the associated factors in female patients with breast cancer in Turkey. Methods: Data was acquired from a questionnaire involving 535 patients who applied to 14 various oncology clinics in Turkey between 1st and 28th of February 2010. Analyses were performed by the participating clinics and were divided into 3 groups: centers located in metropolitan areas formed group I (n=161), those located in Marmara and central Anatolia region formed group 2 (n=189), and centers located in Karadeniz and East-Southeast Anatolia region formed group 3 (n=185). The groups of these centers were formed according to the socioeconomic development of the provinces. Results: The median patient age was 48 years, 56.1% of patients were less than 50 years of age. Eighty-five percent of the patients detected a mass in their breast by self examination and 27% of the patients older than 50 years never had breast imaging until the definite diagnosis was established. The median time elapsed between disease noticed by the patient and application to a health care center was 10 days, between application and biopsy 19 days, between biopsy and surgery 10 days, and between surgery and systemic therapy 31 days. The median time elapsed between patients applying for surgery in groups I and 2 centers was 11 and 21 days, respectively (p=0.01). The median time elapsed between biopsy and surgery in groups 1,2 and 3 centers was 14,1.5, and 12 days, respectively (p<0.05). Conclusion: A high level of awareness regarding breast cancer in our country is related with the time that is defined as 10 days between disease recognition and medical application. The time elapsed between the application and biopsy, surgery and systemic therapy was longer compared with the corresponding figures in developed countries.Öğe Assessment of sleep quality and psychological characteristics in patients with temporomandibular disorders(Karger, 2013) Oflaz, S.; Guveli, H.; Bakay, H.; Bolek, S.; Ucar, D.; Tatar, Z. B.; Ozkan, M.[Abstract Not Available]Öğe The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)(Amer Soc Clinical Oncology, 2011) Akbulut, H.; Altundag, M. K.; Saip, P.; Coskun, H. S.; Camci, C.; Ozkan, M.; Paydas, S.[Abstract Not Available]Öğe Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience(Aepress Sro, 2012) Ozkan, M.; Berk, V.; Kaplan, M. A.; Benekli, M.; Coskun, U.; Bilici, A.; Gumus, M.This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies. Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.Öğe Is there an association between childhood trauma and depression in patients with Myofascial Pain Syndrome?(Karger, 2013) Oflaz, S.; Guveli, H.; Bakay, H.; Bolek, S.; Ucar, D.; Tatar, Z. B.; Ozkan, M.[Abstract Not Available]Öğe Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA)(Elsevier Sci Ltd, 2015) Ozkan, M.; Cicin, I.; Ozaslan, E.; Benekli, M.; Oksuzoglu, B.; Kocer, M.; Isikdogan, A.[Abstract Not Available]Öğe Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey(Elsevier Sci Ltd, 2013) Budakoglu, B.; Altundag, K.; Berk, V.; Ozkan, M.; Algin, E.; Dogu, G. G.; Harputluoglu, H.[Abstract Not Available]Öğe Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer(Amer Soc Clinical Oncology, 2011) Saip, P.; Eralp, Y.; Ozkan, M.; Karaca, H.; Benekli, M.; Cetin, B.; Isikdogan, A.[Abstract Not Available]Öğe Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial(Churchill Livingstone, 2013) Saip, P.; Eralp, Y.; Sen, F.; Karaca, H.; Ozkan, M.; Cetin, B.; Benekli, M.Background: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer. Methods: Twenty-nine patients were enrolled. The primary objectives were response and clinical benefit (CB) rates, secondary objectives were toxicity, response duration and progression free survival. Patients received 1250 mg oral lapatinib continuously once daily and intravenous vinorelbine 20-25 mg/m(2) on days 1 and 8, every 3 weeks. Results: Although 25 patients were evaluable for response, according to intend to treat analysis of 28 patients; 14% had confirmed partial response (PR) and 36% had stable disease more than 24 weeks with a CB rate of 50%. Sixty four percent of the patients suffered from grade 3-4 hematologic and 18% from grade 3 extra-hematologic toxicities. Conclusion: The results of this trial provide evidence to further investigate the potential of this combination for patients unsuitable for trastuzumab or who become refractory to trastuzumab. (C) 2013 Elsevier Ltd. All rights reserved.Öğe Relationship between endothelial dysfunction and prosthetic heart valve thrombosis: a preliminary investigation(Verduci Publisher, 2013) Kaya, H.; Ozkan, M.; Yildiz, M.AIM: The etiopathogenesis of prosthetic heart valve thrombosis (PHVT) is multifactorial. Since the relationship between PHVT and endothelial function is never studied, we aimed to analyze the role of endothelial function in patients with PHVT. PATIENTS AND METHODS: Twenty-two patients with PHVT (14 female, 31.8% with atrial fibrillation, mean age 46.0 +/- 12.2) and 22 controls with prosthetic heart valves (17 female, 36.4% with atrial fibrillation, mean age 45.7 +/- 11.5) were prospectively evaluated. Two groups had similar demographic and echocardiographic characteristics. Endothelial function was evaluated in all patients by the non-invasive measurement of flow mediated dilatation (FMD) of brachial artery. High-resolution ultrasound was used to measure brachial artery diameter at rest, during reactive hyperemia (endothelium-dependent, FMD), and following sublingual administration of nitroglycerin (endothelium-independent, nitroglycerin-mediated vasodilatation, NMD). RESULTS: Functional capacity at presentation determined as mean NYHA functional capacity class was worse in patients with PHVT than in control group (2.1 +/- 0.6 vs. 1.3 +/- 0.6; p < 0.0001). FMD was significantly reduced in patients with PHVT compared with control group (4.01 +/- 1.52 vs. 8.48 +/- 3.37; p < 0.0001). NMD did not differ between two groups (11.77 +/- 2.30 vs. 13.38 +/- 3.50; p = 0.08). FMD level of < 5.65 predicted prosthetic valve thrombosis with an 82% sensitivity and 77% specificity (area under the curve = 0.888, p < 0.0001). CONCLUSIONS: This study demonstrated the endothelial dysfunction in patients with PHVT compared with well-matched control group. In this study, we found that patients with PHVT have endothelial dysfunction which might contribute to the development of thrombosis.Öğe Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta(Wiley, 2014) Karatayli, S. C.; Ulger, Z. E.; Ergul, A. A.; Keskin, O.; Karatayli, E.; Albayrak, R.; Ozkan, M.No data exist to assess certain polymorphisms that have a potential effect on the immune response in patients with chronic hepatitis delta (CHD). The aim of this study was to investigate polymorphisms in 6 polymorphic sites: IL-10 -1082 (rs1800896), IL-10 -627 (rs1800872), IFN-gamma +874 (rs62559044), TNF-alpha -308 (rs1800629), vitamin D receptor (VDR) FokI (rs2228570) and VDR TaqI (rs731236). The genotypes of 67 patients with CHD and 119 patients with chronic hepatitis B (CHB) were compared. In addition, 56 individuals with resolved hepatitis B virus (HBV) infection were used as a control group for patients with CHB. Polymorphisms in TNF-alpha, IL-10, and VDR genes were analysed using polymerase chain reaction/restriction fragment length polymorphism methods. The IFN-gamma gene polymorphism was detected by allele-specific polymerase chain reaction (PCR). Patients with CDH were more likely to have advanced liver disease compared with patients with CHB (P<0.0001). IL-10 -1082 and VDR TaqI polymorphisms showed significant differences between patients with CHD and CHB. The high secretory IL-10 -1082 genotype GG was less frequent in CHD compared with patients with CHB and resolved HBV (17.7%, 37.4% and 47.1%, respectively (PCHD vs CHB and resolved HBV). The frequency of the high secretory VDR TaqI TT genotype was 86.6% in patients with CHD, 62.7% in patients with CHB and 62.5% in resolved HBV individuals (CHD vs CHB: P<0.05). None of the polymorphisms analysed had an effect on HBV persistence. IL-10 -1082 and VDR TaqI polymorphisms may contribute to the more severe liver disease associated with CHD compared with CHB.
